Activating mutations of K-ras are frequent in colon tumors and aberrant crypt foci, and may play important roles in colon carcinogenesis. Here, we investigated the effects of a K-ras codon 12 mutation on inducible nitric oxide synthase (iNOS) expression. When rat intestinal epithelial cells (IEC-6) were transfected with K-ras 
Introduction
Activating mutations of K-ras are frequent in aberrant crypt foci (ACF) and colon tumors in humans and in the azoxymethane (AOM)-induced rat colon carcinogenesis model (Yamashita et al., 1995; Takahashi et al., 2000) . It has also been reported that K-ras mutations and/or activation increase the expression of cyclin D1 and cyclooxygenase-2 (COX-2) in AOM-induced rat colon tumors (Bissonnette et al., 2000) .
Oncogenic mutations in Ras result in the activation of downstream signaling proteins such as elements in the Raf/MEK/MAPK and PI3K/Akt/PKB pathways (Campbell et al., 1998) . Cyclin D1 and COX-2 are known to be regulated through a cAMP-responsive element-binding protein (CREB)-dependent pathway that is activated by the MAPK-kinase cascade (D'Amico et al., 2000; Shao et al., 2000; Slice et al., 2000) . COX-2 expression is also increased by the binding of c-Jun to the cAMP-responsive element (CRE) or of the CCAAT/enhancer-binding protein b (C/EBPb) to the nuclear factor for the interleukin-6 regulatory element (NF-IL6) through the activation of the MEKK/ SEK/JNK and Raf/MEK/ERK pathways, respectively (Shao et al., 2000; Sheng et al., 2001) . COX-2 is further regulated post-transcriptionally through Akt/PKB activation (Shao et al., 2000; Sheng et al., 2001) . Moreover, oncogenic Ras enhances NF-kB activation (Norris and Baldwin, 1999; Arsura et al., 2000) , which is involved in the induction of COX-2 by interleukin-1b (IL-1b) and lipopolysaccharide (LPS) (Kojima et al., 2000; Mifflin et al., 2002) .
It is known that inducible nitric oxide synthase (iNOS) is also regulated by CREB, AP-1, C/EBPb, and NF-kB in some cells (Eberhardt et al., 1998) . In rat colon carcinogenesis induced by AOM, we earlier found that iNOS expression is increased from an early stage . However, hitherto it has not been clarified whether K-ras mutations affect the expression of iNOS. Here, we therefore investigated the effects of transfection of an activated K-ras mutant, K-ras
Asp12
, on iNOS expression in intestinal epithelial cells. As a result, we found the activated K-ras mutant to enhance markedly iNOS expression mediated by IL-1b or LPS. Based on the data obtained, we conclude the significance of nitric oxide (NO) production by iNOS in the growth of K-ras-transformed cells.
Results

Induction of iNOS expression by IL-1b and LPS in K-ras
Asp12
-transfected IEC-6 cells IEC-6 rat intestinal epithelial cells were transfected with K-ras WT or K-ras Asp12 cDNA, and stable transfectants (IEC-6/K-ras WT cells and IEC-6/K-ras Asp12 cells) were selected with G418 treatment. The basal and IL-1b or LPS-stimulated levels of the iNOS protein were determined by immunoblot analysis (Figure 1 ). Immunoreactive bands for iNOS (MW 130 kDa) were hardly detectable in the nontreated IEC-6 cells and stable IEC-6/vector, IEC-6/K-ras WT , and IEC-6/K-ras Asp12 transfectants. Treatment of the cells with 10 ng/ml of IL-1b for 6 h induced a marked expression of iNOS in IEC-6/ K-ras Asp12 cells, whereas only faint bands were detected with the IEC-6, IEC-6/vector, and IEC-6/K-ras WT cells. Treatment with 100 ng/ml of LPS for 6 h also induced iNOS expression in IEC-6/K-ras Asp12 cells, but not in the IEC-6, IEC-6/vector, and IEC-6/K-ras WT cases ( Figure 1a) . After 24 h incubation, iNOS expression was still observed and rather increased in IL-1b-or LPStreated IEC-6/K-ras Asp12 transfectants, but not in the other cells (Figure 1b) .
NO production in IEC-6/K-ras Asp12 cells
Griess assays demonstrated NO production in IEC-6/Kras Asp12 cells to be increased dose dependently by IL-1b and LPS treatment (Figure 2a, b) . MTT assays for cell viability showed that cell proliferation was not enhanced by treatment with IL-1b and LPS, but rather decreased, probably in association with elevated NO production (Figure 2c, d ).
Reporter gene assay for iNOS promoter-dependent transcriptional activity
To examine the regulatory elements involved in the expression of iNOS in IEC-6/K-ras Asp12 cells, we constructed plasmids in which the wild-type and mutation-generated rat iNOS promoter regions (bp À2001 to þ 157) were ligated in front of the luciferase reporter in the pB2-BSD vector. There are two binding sites for NF-kB (A: bp À91 to À81; B: bp À949 to À939), and the C/EBP and CREB/ATF-like binding consensus sites overlap each other (bp À156 to À147). Luciferase activity of the cells in which the plasmid constructs were transiently transfected was about 10 times higher in the case of the wild-type rat iNOS promoter-ligated construct than with the promoterless control vector. The iNOS promoter activity analysed using the wild-type iNOS promoter region was elevated more than six times in IEC-6/K-ras Asp12 cells treated with IL-1b or LPS compared to nontreated IEC-6/K-ras Asp12 cells (Figure 3) . Mutation of the construct in the NF-kBbinding sequence nearest the C/EBP-b and CREB/ATFlike binding sites (NF-kB (A)-mutant) resulted in a decrease in the promoter activity to about two-thirds of the value of the wild-type construct in the steady state, and the elevation by treatment with IL-1b or LPS was about four times. As a result, the promoter activity of the NF-kB (A) mutant construct in the presence of IL1b or LPS was about 40% of that of the wild type. The mutation in another NF-kB binding sequence (NF-kB (B)-mutant) did not influence the promoter activity. The mutations in the C/EBP and CREB/ATF-like binding sites (CREB/ATF and C/EBP-mutant) and in a CREB/ ATF-like binding site (CREB/ATF-mutant) reduced the enhancement of the promoter activity by IL-1b or LPS Figure 1 Immunoblot analysis of cell lysates. IEC-6 cells and stable IEC-6/vector, IEC-6/K-ras WT and IEC-6/K-ras Asp12 transfectants were incubated in basal medium (lanes, Cont) or treated with 10 ng/ml IL-1b (lanes, IL-1b) or 100 ng/ml LPS (lanes, LPS) for 6 h (a) or 24 h (b). Aliquots of 100 mg of total cellular protein were electrophoresed on a 5-20% gradient SDS-polyacrylamide gel and transferred on to a membrane filter for incubation with specific monoclonal antibodies: (A) anti-iNOS; (B) anti-actin to about two-thirds of the value with the wild-type construct, although they did not influence the promoter activity in the steady state. The construct with a mutation in the binding sequence for C/EBPb (C/EBPmutant) also reduced the IL-1b-, but not the LPSenhanced promoter activity. These results indicate that the NF-kB binding site (A) and the upstream C/EBPb and CREB/ATF-like binding sites are important for the elevation of the iNOS promoter activity by IL-1b or LPS in IEC-6/K-ras Asp12 cells.
Enhancement of the DNA-binding activity of NF-kB
The binding activity of NF-kB to the NF-kB binding consensus site (A: bp À81 to À91) of the rat iNOS promoter region in the IEC-6/vector, IEC-6/K-ras WT and IEC-6/K-ras Asp12 cells was examined. Nuclear extracts from cells treated with 10 ng/ml of IL-1b or 100 ng/ml of LPS for 6 h demonstrated binding to the probe DNA in the IEC-6/vector, IEC-6/K-ras WT and IEC-6/K-ras Asp12 cells (Figure 4 ). The binding activities were high in IEC-6/K-ras Asp12 and intermediate in IEC-6/K-ras WT as compared to the IEC-6/vector cells. Bands for nuclear protein binding disappeared in the presence of an excess unlabeled NF-kB-WT probe, while addition of excess unlabeled NF-kB-mu did not decrease their intensity, indicating that the binding activity is specific for the NF-kB site. The addition of anti-p50 and antip65 antibodies decreased the bands and induced supershifts, showing that the IL-1b and LPS-induced bands are derived from the binding of NF-kB consisting of p50 and p65. Moreover, the addition of anti-Jun D antibody also decreased the band, indicating that Jun D might form a complex with NF-kB.
Changes in the transcription factor binding to a CRE-like site
The binding activities to C/EBP and CRE/ATF-like binding consensus sites (bp À172 to À142) of the rat iNOS promoter region in the IEC-6/vector, IEC-6/ K-ras WT and IEC-6/K-ras Asp12 cells were examined. The binding activity to an oligonucleotide probe including this region was detected in nuclear extracts even from the nonstimulated IEC-6/vector, IEC-6/K-ras WT and IEC-6/K-ras Asp12 cells ( Figure 5 ). IL-1b and LPS somewhat affected the binding activity. There were several bands observed (bands a-f in Figure 5 ), and the pattern slightly differed among the IEC-6/vector, IEC-6/ K-ras WT , and IEC-6/K-ras Asp12 cells. The bands disappeared in the presence of excess unlabeled CREB/ATF-C/EBP-WT probe. The addition of excess unlabeled CREB/ATF-C/EBP-mu did not decrease their intensity, while excess unlabeled CREB/ATF-mu or C/EBP-mu caused a slight and marked decrease, respectively, indicating most binding activity to be specific for CREB/ATF-like sites, with some dependent on C/EBP sites. The addition of antibodies against Jun D, ATF-1, ATF-2, C/EBPb, CREB-1, and CREM-1 decreased the bands (d-f), (b), (f), (a, b, and e), (b, c, and e), and (b and c), respectively, and anti-JunD, anti-ATF-1, anti-C/ EBPb, anti-CREB-1, and anti-CREM-1 antibodies induced supershifts.
Expression levels of transcription factors involved in iNOS expression in IEC-6/K-ras Asp12 cells
The protein levels in the cytoplasm and nuclear extracts for transcription factors that can bind the consensus Figure 3 Effects of IL-1b-or LPS-treatment on transcriptional activities of wild-type or mutated rat iNOS promoter constructs fused to a luciferase reporter gene transiently transfected in IEC-6/K-ras Asp12 cells. At 24 h after transfection of reporter plasmids (0.1 mg each) for wild-type or mutants of rat iNOS promoter regions with 0.1 mg of pcDNA3.1/Hygro/lacZ into IEC-6/K-ras Asp12 cells, the medium was freshly changed to a basal medium (') or a medium containing 10 ng/ml IL-1b ( ) or 100 ng/ml LPS ( ). The mean value of luciferase activity/b-galactosidase activity was calculated with data from duplicate wells and expressed as the % of the wild-type rat iNOS promoter activity in the steady state. Similar results were obtained from two separate experiments P-labeled oligonucleotide probe for the NF-kB binding site in the rat iNOS promoter region, and electrophoresed on a 5% polyacrylamide gel. Shifted bands by IL-1b-or LPS-treatment disappeared specifically on the addition of a 100-fold excess unlabeled competitor oligonucleotide. Preincubation of the nuclear extracts with anti-NF-kB antibody for 1 h at 41C induced supershifts Figure 5 Binding activities to C/EBP and CRE/ATF-like binding consensus sites of the rat iNOS promoter region in the IEC-6/ vector, IEC-6/K-ras WT , and IEC-6/K-ras Asp12 cells. Nuclear extracts from cells at steady state (lanes 1), or treated with IL-1b (lanes 2) or LPS (lanes 3) for 6 h were incubated for 30 min at 41C with a 32 P-labeled oligonucleotide probe, and electrophoresed on a 5% polyacrylamide gel. For competition assays, a 100-fold excess of unlabeled oligonucleotide with wild-type or mutated sequences was added in the reaction mixture. For supershift assays, nuclear extracts were preincubated with specific antibodies for 1 h at 41C sites for NF-kB, CREB/ATF, and C/EBP were analysed by immunoblotting (Figure 6a) . In IEC-6/K-ras Asp12 cells, the levels of ATF-2, CREB-1, NF-kB p65 and p50, and to a lesser extent, ATF-1 were increased in the nuclear extract compared to the IEC-6/vector and/or IEC-6/K-ras WT cases. NF-kB p65 and p50, and C/EBPb were increased in each transfectant in the presence of IL1b or LPS. The levels of phosphorylated JNK (pJNK) and phosphorylated ERK (pERK), which are known to activate transcriptional factors such as ATF, CREB/ CREM, and C/EBP, were elevated in the IEC-6/Kras Asp12 cells compared to the IEC-6/vector and IEC-6/ K-ras WT cases, and enhanced in the presence of IL-1b or LPS (Figure 6b ).
Elevation of anchorage-independent growth of IEC-6/K-ras Asp12 cells by IL-1b and LPS, and its suppression by NOS inhibitors Assays of colony formation in soft agar demonstrated an anchorage-independent growth of the IEC-6/Kras Asp12 cells, and the addition of IL-1b or LPS markedly increased the number of colonies formed. On the other hand, the IEC-6/vector and IEC-6/K-ras WT cells did not demonstrate any capacity for anchorage-independent growth, with or without IL-1b or LPS treatment (Figure 7a ). To examine the involvement of NO production in the colony formation of IEC-6/K-ras Asp12 cells, NOS inhibitors were added to the soft-agar medium. The result was that 500 mM L-NAME, 50 mM L-NIL, and 50 mM ONO-1714 decreased the number of colonies (Figure 7b ).
Suppressive effects of NOS inhibitors on the in vivo growth of IEC-6/K-ras Asp12 cells in nude mice
The subcutaneous injection of IEC-6/K-ras Asp12 cells into nude mice caused tumor formation, and the measured volumes of tumors were reduced in mice fed diets containing 100 p.p. m. L-NAME or 50 p.p.m. ONO-1714 (Figure 8a ). The final weights of tumors in mice fed diets containing 100 p.p.m. L-NAME and 50 p.p.m. ONO-1714 were 57% (Po0.05) and 46% (Po0.01), respectively, of the control value (Figure 8b ). Obvious Figure 6 Protein levels in the cytoplasm and nuclear extracts, or in total cell lysates, of the IEC-6/vector, IEC-6/K-ras WT , and IEC-6/ K-ras Asp12 cells. (a) Transcription factors that can bind to consensus sites for NF-kB, CREB/ATF, and C/EBP, and (b) phosphorylated JNK and ERK. Aliquots of 50 mg proteins from cytoplasmic and nuclear fractions in the steady state (lanes 1), or after treatment with IL-1b (lanes 2) or LPS (lanes 3) for 6 h were electrophoresed on a 5-20% gradient SDS-polyacrylamide gel, and transferred on to a membrane filter. After incubation with specific monoclonal antibodies, immunoreactive bands were detected using a chemiluminescence system K-ras mutation elevates iNOS expression M Takahashi et al toxic effects of 100 p.p.m. L-NAME or 50 p.p.m. ONO-1714 were not observed. The parental IEC-6 cells and IEC-6/K-ras WT cells did not form tumors within 12 weeks after subcutaneous injection into nude mice (1 Â 10 6 cells/mouse, three animals in each group). The expression of iNOS in tumors formed by the IEC-6/Kras Asp12 cells was confirmed by RT-PCR and Western blotting (data not shown).
Discussion
The present study demonstrated that the transfection of an activated mutant of K-ras, K-ras Asp12 , can result in the enhancement of the iNOS expression mediated by IL-1b or LPS. K-ras Asp12 features a mutation of G to A at the second base of codon 12 of the K-ras gene, which is frequently observed in colon tumors and ACF in rats and humans (Yamashita et al., 1995; Takahashi et al., 2000) . To our knowledge, the present report is the first to provide concrete evidence that an activating mutation of K-ras can influence the iNOS expression in intestinal epithelial cells. Moreover, the present study showed that NOS inhibitors decrease the colony formation of the Kras-transformed cells in soft agar and tumor development in nude mice, indicating an important role for NO in cell growth.
Recently, several authors have suggested an involvement of Ras in the iNOS expression. For example, it has been reported that a dominant-negative mutant of p21 (ras) inhibits the induction of iNOS by inhibiting the activation of NF-kB in primary astrocytes (Pahan et al., 2000) . It has also been documented that inhibitors of the mevalonate pathway, which block the farnesylation of Ras, inhibit LPS-and the cytokine-mediated expression WT , and IEC-6/Kras Asp12 cells were inoculated in basal soft-agar medium (') or softagar medium containing 10 ng/ml IL-1b ( ) or 100 ng/ml LPS ( ); (b) IEC-6/K-ras Asp12 cells were inoculated in basal soft-agar medium (') or soft-agar medium containing 10 ng/ml IL-1b ( ) or 100 ng/ml LPS ( ). NOS inhibitors, L-NAME, L-NIL and ONO-1714, were also added to soft-agar medium at concentrations of 500, 50, and 50 mM, respectively. The numbers of colonies were counted after 2 weeks of incubation. The data presented are mean7s.e. values (n ¼ 2). Similar results were obtained from three separate experiments: *significantly different from the control case at Po0.05 K-ras mutation elevates iNOS expression M Takahashi et al of iNOS (Pahan et al., 1997) . Moreover, Clostridium sordellii lethal toxin-82, that inactivates small Gproteins such as Ras, has been shown to inhibit IL-1b-mediated NO release in insulin-secreting clonal beta cells (Tannous et al., 2001) . These reports suggest that the activation of Ras without mutations may also play an essential role in cytokine-mediated iNOS expression in nontransformed cells, although the transfection of wildtype K-ras cDNA into IEC-6 cells did not elevate the iNOS expression and colony formation even in the presence of IL-1b or LPS in the present study. The promoter region of the rat iNOS gene contains several binding sites for transcription factors, such as NF-kB, C/EBPb, and CREB/ATF, and these factors are suggested to regulate IL-1b-mediated iNOS expression cooperatively (Eberhardt et al., 1998; Bhat et al., 2002) . It has been reported that the activation of extracellular signal-related kinase (ERK), a member of the MAPK family, is necessary for the induction of iNOS by IL-1b in cardiac myocytes and microvascular endothelial cells (Singh et al., 1996) . Recently, it was also reported that the activation of ERK is required for persistent NF-kB activation by IL-1b in rat vascular smooth muscle cells (Jiang et al., 2001) . Indeed, the analysis of regulatory elements involved in the expression of iNOS in IEC-6/ K-ras Asp12 cells demonstrated the importance of binding of NF-kB to the consensus sequence. Moreover, C/ EBPb, and CREB/ATF-like binding sites also were suggested to be involved in the elevation of iNOS promoter activity by IL-1b or LPS in the IEC-6/Kras ASP12 cells, and at least Jun D, ATF-1, ATF-2, C/ EBPb, CREB-1, and CREM-1 could be shown to bind to the sequence. As the activity of these transcription factors is known to be regulated by phosphorylation, binding itself may not always result in activated transcription. The nuclear protein levels of NF-kB p65 and p50, ATF-2, ATF-1, and CREB-1 were higher in the IEC-6/K-ras Asp12 cells than in the IEC-6/vector and/ or IEC-6/K-ras WT cells. It has been reported that IL-1b-mediated JNK activation results in the phosphorylation of ATF-2, c-Jun, and Jun D (Cirillo et al., 1999) . ATF-2 is known to form heterodimers with Jun, and has an intrinsic histone acetyltransferase activity (Kawasaki et al., 2000) . Furthermore, Jun D increases NF-kB transactivation by functional cooperation with NF-kB p65 (Rahmani et al., 2001) . Indeed, the interaction of Jun D with NF-kB was suggested by the gel-retardation assay in the present study. Therefore, the observed IL1b-and LPS-mediated iNOS expression in K-ras Asp12 -transfected IEC-6 cells may be linked with the activation of NF-kB and other factors, at least ATF-2 and Jun D, mediated by MAPK.
It was demonstrated here that an activating mutation of K-ras is itself not sufficient for the induction of iNOS expression, treatment with IL-1b or LPS being needed. This suggests that iNOS expression might be induced in intestinal epithelial or other cells having an activating mutation of K-ras under chronic inflammatory conditions. In AOM-induced ACF in the rat colon, K-ras mutations are quite frequent, although most of the lesions lack iNOS expression (Takahashi et al., 2000) .
Since it is well established that NOS inhibitors can suppress ACF formation (Rao et al., 1999; Kawamori et al., 2000) , it is probable that iNOS could be induced in K-ras-activated ACF by cytokines from surrounding inflammatory cells and promote tumor formation.
The IL-1b-or LPS-mediated expression of iNOS did not enhance, but rather suppressed, the growth of Kras
Asp12
-transfected cells in standard in vitro culture, but enhanced colony formation in soft agar, in the present study. Furthermore, NOS inhibitors were found to suppress colony formation in soft agar and tumor development in nude mice. There has been a report that colon cancer cells engineered to generate NO continuously grow more slowly than the wild-type parental cells in vitro, but the tumors from these cells grow faster than those derived from wild-type cells and are markedly more vascularized (Jenkins et al., 1995) . Furthermore, iNOS inhibition may reduce the growth of colon cancer cells in nude mice (Thomsen et al., 1997) . In this context, it should be noted that K-ras mutations are relatively more frequent in large than in small tumors in the colons of rats treated with AOM and in human colon adenomas (Ichii et al., 1993) . There is a possibility that NO production by iNOS may be one of the mechanisms underlying the tumor-promoting effects of activated K-ras. Indeed, increased iNOS expression has been observed in human colorectal (Ambs et al., 1998) , non-small-cell lung (Liu et al., 1998) , and pancreatic tumors (Vickers et al., 1999) , in which K-ras mutations are frequent (Adjei, 2001 ).
In conclusion, the transfection of K-ras with an activating mutation enhanced iNOS expression mediated by IL-1b or LPS in an intestinal epithelial cell line through the activation of promoters on NF-kB, C/EBP, and CRE-like sites, suggesting the involvement of NO production by iNOS in the tumor-promoting effects of activated K-ras. iNOS inhibitors are thus possible candidate agents for the prevention of cancers featuring K-ras activation. Further studies of links among K-ras activation, cytokine expression, and iNOS are clearly warranted.
Materials and methods
Cell culture, cytokine treatment, and chemicals
A rat intestinal epithelial cell line, IEC-6 (Quaroni et al., 1979) , was obtained from Dainippon Pharmaceutical Co., Ltd (Osaka, Japan), and a rat colon cancer cell line, RCN-9 (Inoue et al., 1991) , was obtained from RIKEN Cell Bank (Saitama, Japan). The cells were maintained in RPMI-1640 (Iwaki, Japan), supplemented with 5% fetal bovine serum (HyClone Laboratories, Inc., Logan, UT, USA) and 100 U/ml penicillin/streptomycin (GIBCO) at 371C in 5% CO 2 . To induce iNOS expression, they were treated with 10 ng/ml of mouse IL-1b (Sigma Chemical Co., St Louis, MO, USA) or 100 ng/ml of LPS (Sigma Chemical Co.) for 6 or 24 h.
3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) was purchased from Sigma Chemical Co., and L-N G -nitroarginine methyl ester (L-NAME) and L-N 6 -(1-iminoethly) lysine (L-NIL) from Cayman Chemical (Ann Arbor, MI, USA). (1S, 5S, 6R, 7R)-7-Chloro-3-imino-5-methyl-2-azabicyclo [4.1.0]heptane (ONO-1714) was chemically synthesized at Ono Pharmaceutical Co. Ltd (Osaka, Japan).
Construction of plasmids containing rat K-ras gene fragments
RNAs were extracted from the rat colon cancer cell line, RCN-9, bearing a K-ras mutation in codon 12 on one allele, using ISOGEN (Nippon Gene, Inc., Toyama, Japan) and rat K-ras cDNA fragments (665-bp) were amplified with the 5 0 -primer, 5 0 GCCTGCTGAAAATGACTGAG3 0 , and the 3 0 -primer, 5 0 GCTAAAACAAATGCTAATAATTTAGTGTAATGTAC3 0 , using an RNA LA PCR kit (Takara Shuzo Co. Ltd, Shiga, Japan) and inserted into a mammalian expression plasmid vector, pTARGETt (Promega Co., Madison, WI, USA). The nucleotide sequence determined by sequencing was matched with the reported sequence of rat K-ras cDNA (Iritani et al., 1986; Higinbotham et al., 1994) . Plasmids containing rat Kras Asp12 and K-ras WT cDNA fragments were named K-ras 
Immunoblot analysis
The cells were homogenized in RIPA buffer, consisting of 50 mM Tris-HCl, pH 7.5, 150 mM sodium chloride, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 0.02% sodium azide, 1 mM PMSF and 10 mM leupeptin. Aliquots of 100 mg of total cellular protein were electrophoresed on 5-20% gradient SDS-polyacrylamide gels, then transferred to membranes, and probed with monoclonal anti-iNOS antibody (Transduction Laboratories, Lexington, KY, USA) at 1 : 2500 dilution as previously described (Takahashi et al., 1997) . Monoclonal anti pJNK and anti-pERK antibodies (Santa Cruz Biotechnology, Inc., CA, USA) were used at 1 : 500 dilution. Anti-mouse immunoglobulin, a horseradish peroxidase-conjugated F (ab 0 ) 2 fragment from sheep (Amersham, Buckinghamshire, UK; 1 : 2000 dilution), was used as the second antibody. The membranes were developed using a chemiluminescence system (ECL detection reagents; Amersham). To verify the relative protein amounts in each lane, the actin levels were also determined as an internal control with polyclonal rabbit antiactin IgG (Biomedical Technologies Inc., Stoughton, MA, USA; 1 : 1000 dilution) as the primary antibody, and antirabbit immunoglobulin, a horseradish peroxidase-linked F (ab 0 ) 2 fragment from goat (Amersham; 1 : 2000 dilution), as the secondary antibody.
Analysis of NO
NO production was measured by Griess assay (Kiechle and Malinski, 1996) . IEC-6/K-ras Asp12 cells were inoculated at 2 Â 10 4 cells in each well of 96-well plates. After an overnight culture, they were stimulated with IL-1b or LPS at different doses for 24 h. Cultured supernatant (100 ml) was sampled and immediately mixed with 100 ml of Griess reagent, consisting of 1% sulfanilamide, 0.1% naphthalene-ethylenediamine dihydrochloride in 5% phosphoric acid. After 15 min, product formation was colorimetrically determined at 540 nm. As a standard, sodium nitrite was reacted with the Griess reagent.
The cell viability in each culture was determined by the MTT assay. After treatment with IL-1b or LPS, the cells were further incubated in medium containing 0.5 mg/ml of MTT for 1 h. The MTT formazan produced by living cells was dissolved in dimethylsulfoxide and absorbance at 595 nm was measured with a microplate reader (Bio-Rad Laboratories, Hercules, CA, USA).
Plasmid construction for the iNOS promoter reporter gene assay DNA was extracted from normal colon mucosa of a male F344 rat and iNOS promoter region fragments (bp À2001 to þ 157; 2158-bp) were amplified with the 5 0 -primer, 5 0 GTCCAGGG GTGTTATATAATTTGTCGCAGGATAGC3 0 , and the 3 0 -primer, 5 0 CTTGTAGTTGACTAGGCTAACAAGACCCAA GCC3 0 , using an LA PCR kit (Takara Shuzo Co. Ltd, Shiga, Japan) and inserted upstream of the luciferase reporter gene of the pB2-BSD vector, constructed with the PicaGenet basic vector 2 (PGV-B2) (Toyo Ink MFG. Co., Ltd, Tokyo, Japan) and the blasticidin-S deaminase (BSD) gene. The nucleotide sequence determined by sequencing almost matched the reported sequence of rat iNOS promoter DNA (Keinanen et al., 1999) . Mutations at binding sequences for NF-kB, CREB/ATF and c/EBPb were generated using an ExSitet PCR-based site-directed mutagenesis kit (Stratagene, CA, USA). The mutated sequences were the same as those of probes used for the electrophoretic mobility shift assay (EMSA) shown below.
Reporter gene assay for iNOS promoter-dependent transcriptional activity IEC-6/K-ras Asp12 cells were inoculated at 1.25 Â 10 4. cells in each well of 24-well plates. After an overnight culture, reporter plasmids (0.1 mg each) for wild-type or mutant rat iNOS promoter regions were cotransfected with 0.1 mg of pcDNA3.1/ Hygro/1acZ (Invitrogen, CA, USA) using the Effectene Transfection Reagent (QIAGEN, Tokyo, Japan). After incubation with the transfection reagent for 24 h, the cells were washed with a fresh medium and treated with 10 ng/ml of IL-1b or 100 ng/ml of LPS (Sigma Chemical Co.) for 24 h. Cell lysis buffer was added to the cells and the luciferase activity was determined using a PicaGenet kit (Toyo Ink MFG. Co., Ltd). For normalization of transfection efficiency, b-galactosidase activity was determined by a colorimetric assay using onitrophenyl-b-D-galactopyranoside. The mean values of luciferase activity/b-galactosidase activity were calculated from data for triplicated wells and expressed as the % of the wildtype rat iNOS promoter activity in the steady state.
Electrophoretic mobility shift assay (EMSA)
The wild-type and mutated NF-kB sites and CREB/ATF-like sites of the rat iNOS promoter were synthesized as complementary oligodeoxynucleotide strands for EMSA. The positive strands of the double-stranded oligonucleotides corresponding to identical regions of the rat iNOS promoter were as follows: wild-type NF-kB site (NF-kB-WT), (bp -96 to À71) 5 0 -CTACTGGGGACTCTCCCTTTGGGAAC-3 0 ; mutated NF-kB site (NF-kB-mu), 5 0 -CTACTGTAGACTCTCCCTT TGGGAAC-3 0 ; wild-type C/EBP-b (boxed in) and CREB/ ATF-like (boldfaced) sites (CREB/ATF-C/EBP-WT), (bp À172 to À142) 5 0 -GAAGATACACCACAGAG AC T AATGC-3 0 ; mutated C/EBP-b and CRE/ATF-like sites (CREB/ATF-C/EBP-mu), 5 0 -GAAGATACACCACAGAG
